Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling

M Ceccon, M Mauri, L Massimino, G Giudici, R Piazza, C Gambacorti-Passerini, L Mologni

Research output: Contribution to journalArticle

Abstract

Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, mutations, or other bypass mechanisms. Recently a growing number of papers showed how, in some cases, resistance due to oncogene overexpression may be associated with drug addiction: cells able to proliferate in the presence of high TKI doses become also TKI dependent, undergoing cellular stress, and apoptosis/death upon drug withdrawal. Notably, if a sub-cellular population survives TKI discontinuation it is also partially re-sensitized to the same drug. Thus, it is possible that a subset of patients relapsing upon TKI treatment may benefit from a discontinuous therapeutic schedule. We focused on two different hematologic malignancies, chronic myeloid leukemia (CML) and anaplastic large cell lymphoma (ALCL), both successfully treatable with TKIs. The two models utilized (LAMA and SUP-M2) differed in having oncogene overexpression as the sole cause of drug resistance (CML), or additionally carrying kinase domain mutations (ALCL). In both cases drug withdrawal caused a sudden overload of oncogenic signal, enhanced mitochondria activity, induced the release of a high amount of reactive oxygen species (ROS), and caused genotoxic stress and massive cell death. In LAMA cells (CML) we could rescue the cells from death by partially blocking downstream oncogenic signaling or lowering ROS detrimental effect by adding reduced glutathione. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
Original languageEnglish
Article number509
JournalCancers
Volume10
Issue number12
DOIs
Publication statusPublished - 2018

Fingerprint

Protein-Tyrosine Kinases
Reactive Oxygen Species
Phosphotransferases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anaplastic Large-Cell Lymphoma
Oncogenes
Cell Death
Pharmaceutical Preparations
Mutation
Gene Amplification
Hematologic Neoplasms
Therapeutics
Switzerland
Drug Resistance
DNA Damage
Substance-Related Disorders
Glutathione
Appointments and Schedules
Mitochondria
Apoptosis

Cite this

Ceccon, M., Mauri, M., Massimino, L., Giudici, G., Piazza, R., Gambacorti-Passerini, C., & Mologni, L. (2018). Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling. Cancers, 10(12), [509]. https://doi.org/10.3390/cancers10120509

Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling. / Ceccon, M; Mauri, M; Massimino, L; Giudici, G; Piazza, R; Gambacorti-Passerini, C; Mologni, L.

In: Cancers, Vol. 10, No. 12, 509, 2018.

Research output: Contribution to journalArticle

Ceccon, M, Mauri, M, Massimino, L, Giudici, G, Piazza, R, Gambacorti-Passerini, C & Mologni, L 2018, 'Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling', Cancers, vol. 10, no. 12, 509. https://doi.org/10.3390/cancers10120509
Ceccon, M ; Mauri, M ; Massimino, L ; Giudici, G ; Piazza, R ; Gambacorti-Passerini, C ; Mologni, L. / Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling. In: Cancers. 2018 ; Vol. 10, No. 12.
@article{b8bdadf51b934fd9a51d169713d3764f,
title = "Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling",
abstract = "Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, mutations, or other bypass mechanisms. Recently a growing number of papers showed how, in some cases, resistance due to oncogene overexpression may be associated with drug addiction: cells able to proliferate in the presence of high TKI doses become also TKI dependent, undergoing cellular stress, and apoptosis/death upon drug withdrawal. Notably, if a sub-cellular population survives TKI discontinuation it is also partially re-sensitized to the same drug. Thus, it is possible that a subset of patients relapsing upon TKI treatment may benefit from a discontinuous therapeutic schedule. We focused on two different hematologic malignancies, chronic myeloid leukemia (CML) and anaplastic large cell lymphoma (ALCL), both successfully treatable with TKIs. The two models utilized (LAMA and SUP-M2) differed in having oncogene overexpression as the sole cause of drug resistance (CML), or additionally carrying kinase domain mutations (ALCL). In both cases drug withdrawal caused a sudden overload of oncogenic signal, enhanced mitochondria activity, induced the release of a high amount of reactive oxygen species (ROS), and caused genotoxic stress and massive cell death. In LAMA cells (CML) we could rescue the cells from death by partially blocking downstream oncogenic signaling or lowering ROS detrimental effect by adding reduced glutathione. {\circledC} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",
author = "M Ceccon and M Mauri and L Massimino and G Giudici and R Piazza and C Gambacorti-Passerini and L Mologni",
year = "2018",
doi = "10.3390/cancers10120509",
language = "English",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "12",

}

TY - JOUR

T1 - Mitochondrial hyperactivation and enhanced ROS production are involved in toxicity induced by oncogenic kinases over-signaling

AU - Ceccon, M

AU - Mauri, M

AU - Massimino, L

AU - Giudici, G

AU - Piazza, R

AU - Gambacorti-Passerini, C

AU - Mologni, L

PY - 2018

Y1 - 2018

N2 - Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, mutations, or other bypass mechanisms. Recently a growing number of papers showed how, in some cases, resistance due to oncogene overexpression may be associated with drug addiction: cells able to proliferate in the presence of high TKI doses become also TKI dependent, undergoing cellular stress, and apoptosis/death upon drug withdrawal. Notably, if a sub-cellular population survives TKI discontinuation it is also partially re-sensitized to the same drug. Thus, it is possible that a subset of patients relapsing upon TKI treatment may benefit from a discontinuous therapeutic schedule. We focused on two different hematologic malignancies, chronic myeloid leukemia (CML) and anaplastic large cell lymphoma (ALCL), both successfully treatable with TKIs. The two models utilized (LAMA and SUP-M2) differed in having oncogene overexpression as the sole cause of drug resistance (CML), or additionally carrying kinase domain mutations (ALCL). In both cases drug withdrawal caused a sudden overload of oncogenic signal, enhanced mitochondria activity, induced the release of a high amount of reactive oxygen species (ROS), and caused genotoxic stress and massive cell death. In LAMA cells (CML) we could rescue the cells from death by partially blocking downstream oncogenic signaling or lowering ROS detrimental effect by adding reduced glutathione. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.

AB - Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, mutations, or other bypass mechanisms. Recently a growing number of papers showed how, in some cases, resistance due to oncogene overexpression may be associated with drug addiction: cells able to proliferate in the presence of high TKI doses become also TKI dependent, undergoing cellular stress, and apoptosis/death upon drug withdrawal. Notably, if a sub-cellular population survives TKI discontinuation it is also partially re-sensitized to the same drug. Thus, it is possible that a subset of patients relapsing upon TKI treatment may benefit from a discontinuous therapeutic schedule. We focused on two different hematologic malignancies, chronic myeloid leukemia (CML) and anaplastic large cell lymphoma (ALCL), both successfully treatable with TKIs. The two models utilized (LAMA and SUP-M2) differed in having oncogene overexpression as the sole cause of drug resistance (CML), or additionally carrying kinase domain mutations (ALCL). In both cases drug withdrawal caused a sudden overload of oncogenic signal, enhanced mitochondria activity, induced the release of a high amount of reactive oxygen species (ROS), and caused genotoxic stress and massive cell death. In LAMA cells (CML) we could rescue the cells from death by partially blocking downstream oncogenic signaling or lowering ROS detrimental effect by adding reduced glutathione. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.

U2 - 10.3390/cancers10120509

DO - 10.3390/cancers10120509

M3 - Article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 12

M1 - 509

ER -